- Home
- GANX vs NSRX Comparison
GANX vs NSRX Comparison
Compare GANX & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GANX
- NSRX
- Stock Information
- Founded
- GANX 2017
- NSRX 2019
- Country
- GANX United States
- NSRX Israel
- Employees
- GANX 25
- NSRX N/A
- Industry
- GANX Biotechnology: Pharmaceutical Preparations
- NSRX Biotechnology: Pharmaceutical Preparations
- Sector
- GANX Health Care
- NSRX Health Care
- Exchange
- GANX Nasdaq
- NSRX Nasdaq
- Market Cap
- GANX 79.8M
- NSRX 73.0M
- IPO Year
- GANX 2021
- NSRX 2025
- Fundamental
- Price
- GANX $2.02
- NSRX $7.02
- Analyst Decision
- GANX Strong Buy
- NSRX Strong Buy
- Analyst Count
- GANX 6
- NSRX 1
- Target Price
- GANX $8.00
- NSRX $22.00
- AVG Volume (30 Days)
- GANX 779.8K
- NSRX 36.4K
- Earning Date
- GANX 11-13-2025
- NSRX 01-01-0001
- Dividend Yield
- GANX N/A
- NSRX N/A
- EPS Growth
- GANX N/A
- NSRX N/A
- EPS
- GANX N/A
- NSRX N/A
- Revenue
- GANX N/A
- NSRX N/A
- Revenue This Year
- GANX N/A
- NSRX N/A
- Revenue Next Year
- GANX N/A
- NSRX N/A
- P/E Ratio
- GANX N/A
- NSRX N/A
- Revenue Growth
- GANX N/A
- NSRX N/A
- 52 Week Low
- GANX $1.41
- NSRX $5.90
- 52 Week High
- GANX $3.19
- NSRX $9.99
- Technical
- Relative Strength Index (RSI)
- GANX 58.27
- NSRX N/A
- Support Level
- GANX $1.74
- NSRX N/A
- Resistance Level
- GANX $2.40
- NSRX N/A
- Average True Range (ATR)
- GANX 0.18
- NSRX 0.00
- MACD
- GANX 0.04
- NSRX 0.00
- Stochastic Oscillator
- GANX 49.72
- NSRX 0.00
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.